{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:49:22Z","timestamp":1782121762045,"version":"3.54.5"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by tear film instability and inflammation. Rebamipide 2% ophthalmic suspension, a mucin secretagogue, has been investigated as a potential treatment due to its unique mechanism targeting mucin deficiency and ocular surface repair.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A systematic search of PubMed, Embase, and Cochrane Library was conducted for studies published between January 2013 and March 2025. Non-randomized and randomized controlled trials evaluating topical 2% rebamipide in patients with DED were included. Outcomes assessed included tear breakup time, Schirmer\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      test, fluorescein staining scores, ocular surface disease index, and adverse events. Data were synthesized using standard meta-analytic techniques and subgroup analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirteen studies, including both randomized and non-randomized trials, were analyzed, comprising a total of 575 participants. Meta-analysis showed that rebamipide nonsignificantly increased tear breakup time at 2 weeks (standardized mean difference [SMD]\u2005=\u20051.04; 95% confidence interval (CI):\u20130.94 to 3.03;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.30;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200589.3%), significant at 4 weeks (SMD\u2005=\u20051.19; 95% CI: 0.74\u20131.64;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200585%) and nonsignificant at 12 weeks (SMD\u2005=\u20050.97; 95% CI:\u20130.15 to 2.08;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.09;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2005=\u200580.1%) indicating enhanced tear film stability. Schirmer\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      test values showed no significant improvement (SMD\u2005=\u20050.04; 95% CI: \u22120.35\u20130.43;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.83), suggesting limited effect on aqueous tear production. Fluorescein staining scores showed a reduction approaching statistical significance (SMD\u2005=\u2005\u22120.68;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.051), while symptom scores measured by ocular surface disease index trended toward improvement, also approaching significance (SMD\u2005=\u2005\u22121.17;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.055). Subgroup analyses revealed greater efficacy in contact lens wearers and postsurgical patients. Safety analysis indicated excellent tolerability, with a high adherence rate (96.8%) and only mild adverse effects such as dysgeusia and nasopharyngitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Rebamipide 2% ophthalmic suspension improves tear stability and ocular surface health in mucin-deficient DED with a favorable safety profile. Further high-quality trials in diverse populations are warranted to confirm its role in global clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048424","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:01:24Z","timestamp":1777629684000},"page":"e48424","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of rebamipide for the treatment of dry eye disease: An updated meta-analysis of randomized and non-randomized controlled trials"],"prefix":"10.1097","volume":"105","author":[{"given":"Meer","family":"Murtaza","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Farooque","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Health Education England, East of England, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Batool","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sir Syed College of Medical Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rasool","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazeer","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karachi Medical and Dental College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Hafsa Qadri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhzan","family":"Ali Akbar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, North Sichuan Medical College, Nanchong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahroz","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karachi Metropolitan University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8099-238X","authenticated-orcid":false,"given":"Tirath","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Trinity Medical Sciences University School of Medicine, Kingstown, Saint Vincent and the Grenadines."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtos.2025.01.010","article-title":"Relative importance of tear homeostatic signs for the diagnosis of dry eye disease.","volume":"36","author":"Wolffsohn","year":"2025","journal-title":"Ocul Surf"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40123-025-01115-0","article-title":"Parainflammation in the ocular system: considerations on the underlying mechanisms and treatment of dry eye disease.","volume":"14","author":"Barabino","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/medicina60091458","article-title":"Epidemiology and risk factors of dry eye disease: considerations for clinical management.","volume":"60","author":"Britten-Jones","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"R4-20260622","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1177\/11206721241305661","article-title":"Mental burden of ocular surface discomfort.","volume":"35","author":"Di Zazzo","year":"2025","journal-title":"Eur J Ophthalmol"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12886-023-03260-1","article-title":"Assessment of the prevalence and risk factors for dry eye symptoms among Romanian medical students using the ocular surface disease index - a cross-sectional study.","volume":"24","author":"Preoteasa","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.3390\/jcm13206060","article-title":"Understanding the dry eye disease-related symptoms in South America: prevalence and associated factors-A systematic review.","volume":"13","author":"Loaiza-Guevara","year":"2024","journal-title":"J Clin Med"},{"key":"R7-20260622","first-page":"e51554","volume":"16","author":"Zarban","year":"2024","journal-title":"Cureus"},{"key":"R8-20260622","first-page":"221","article-title":"Report of the national eye institute\/industry workshop on clinical trials in dry eyes.","volume":"21","author":"Lemp","year":"1995","journal-title":"CLAO J"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1542-0124(12)70081-2","article-title":"The Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye Workshop.","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"R10-20260622","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report.","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R12-20260622","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jamaophthalmol.2014.431","article-title":"Effect of topical rebamipide on human conjunctival goblet cells.","volume":"132","author":"Kase","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R13-20260622","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4103\/IJO.IJO_2586_22","article-title":"Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre.","volume":"71","author":"Jain","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"174891","DOI":"10.1016\/j.ejphar.2022.174891","article-title":"Rebamipide attenuates alcohol-induced gastric epithelial cell injury by inhibiting endoplasmic reticulum stress and activating autophagy-related proteins.","volume":"922","author":"He","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"R15-20260622","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ajo.2013.11.010","article-title":"A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye.","volume":"157","author":"Kinoshita","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"114582","DOI":"10.1016\/j.addr.2022.114582","article-title":"Novel drug delivery systems for the management of dry eye.","volume":"191","author":"Nagai","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"R17-20260622","doi-asserted-by":"crossref","first-page":"DES157","DOI":"10.1167\/iovs.17-23756","article-title":"The ocular surface glycocalyx and its alteration in dry eye disease: a review.","volume":"59","author":"Uchino","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20260622","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jtos.2016.03.003","article-title":"Ocular surface membrane-associated mucins.","volume":"14","author":"Ablamowicz","year":"2016","journal-title":"Ocul Surf"},{"key":"R19-20260622","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jtos.2021.03.003","article-title":"Membrane-associated mucins of the human ocular surface in health and disease.","volume":"21","author":"Martinez-Carrasco","year":"2021","journal-title":"Ocul Surf"},{"key":"R20-20260622","doi-asserted-by":"crossref","first-page":"657327","DOI":"10.3389\/fmed.2021.657327","article-title":"Japan: diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications.","volume":"8","author":"Sotozono","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R21-20260622","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/02713683.2013.834939","article-title":"Regulation of human corneal epithelial mucins by rebamipide.","volume":"39","author":"Itoh","year":"2014","journal-title":"Curr Eye Res"},{"key":"R22-20260622","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.3390\/jcm12227155","article-title":"The efficacy and safety of rebamipide ophthalmic suspension (OPC-12759) in patients with dry eye disease: a systematic review of randomized controlled trials.","volume":"12","author":"Ballesteros-S\u00e1nchez","year":"2023","journal-title":"J Clin Med"},{"key":"R23-20260622","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R24-20260622","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report.","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"R25-20260622","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline.","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"R26-20260622","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R28-20260622","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool.","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"R29-20260622","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","article-title":"Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye.","volume":"32","author":"Koh","year":"2013","journal-title":"Cornea"},{"key":"R30-20260622","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12886-015-0040-0","article-title":"Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.","volume":"15","author":"Ueda","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R31-20260622","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1272\/jnms.82.229","article-title":"Improvements in signs and symptoms of dry eye after instillation of 2% rebamipide.","volume":"82","author":"Igarashi","year":"2015","journal-title":"J Nippon Med Sch"},{"key":"R32-20260622","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/ICO.0000000000000456","article-title":"Effect of rebamipide ophthalmic suspension on intraocular light scattering for dry eye after corneal refractive surgery.","volume":"34","author":"Igarashi","year":"2015","journal-title":"Cornea"},{"key":"R33-20260622","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jop.2016.0096","article-title":"Randomized comparison between rebamipide ophthalmic suspension and diquafosol ophthalmic solution for dry eye after penetrating keratoplasty.","volume":"33","author":"Kobashi","year":"2017","journal-title":"J Ocul Pharmacol Ther"},{"issue":"Suppl 2","key":"R34-20260622","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1097\/ICL.0000000000000438","article-title":"Efficacy of rebamipide instillation for contact lens discomfort with dry eye.","volume":"44","author":"Igarashi","year":"2018","journal-title":"Eye Contact Lens"},{"key":"R35-20260622","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40123-021-00368-9","article-title":"Effects of rebamipide on differences in power and axis of corneal astigmatism between two intra-patient keratometric measurements in dry eyes.","volume":"10","author":"Teshigawara","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"R36-20260622","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40123-022-00523-w","article-title":"Impact of perioperative dry eye treatment with rebamipide versus artificial tears on visual outcomes after cataract surgery in Japanese population.","volume":"11","author":"Teshigawara","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R37-20260622","first-page":"8145731","article-title":"Retrospective observational study on rebamipide ophthalmic suspension on quality of life of dry eye disease patients.","volume":"2019","author":"Sakane","year":"2019","journal-title":"J Ophthalmol"},{"key":"R38-20260622","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40123-022-00457-3","article-title":"The effect of rebamipide on refractive accuracy of cataract surgery in patients with dry eye.","volume":"11","author":"Teshigawara","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R39-20260622","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12886-023-03004-1","article-title":"Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial.","volume":"23","author":"Eom","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"R40-20260622","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1038\/s41598-024-63784-4","article-title":"Comparing two mucin secretagogues for the treatment of dry eye disease: a prospective randomized crossover trial.","volume":"14","author":"Jin","year":"2024","journal-title":"Sci Rep"},{"key":"R41-20260622","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/ICL.0000000000001101","article-title":"Clinical efficacy of 2% rebamipide in patients with video display terminal-associated dry eye disease: a prospective, randomized, double-blinded study.","volume":"50","author":"Lee","year":"2024","journal-title":"Eye Contact Lens"},{"key":"R42-20260622","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","article-title":"Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.","volume":"119","author":"Kinoshita","year":"2012","journal-title":"Ophthalmology"},{"key":"R43-20260622","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ICL.0000000000001001","article-title":"Intraobserver repeatability assessment of the S390L firefly WDR slitlamp in patients with dry eye disease: objective, automated, and noninvasive measures.","volume":"49","author":"Ballesteros-S\u00e1nchez","year":"2023","journal-title":"Eye Contact Lens"},{"key":"R44-20260622","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/ICO.0000000000000940","article-title":"Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes.","volume":"35","author":"Epitropoulos","year":"2016","journal-title":"Cornea"},{"key":"R45-20260622","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3892\/etm.2014.2108","article-title":"Histological observation of goblet cells following topical rebamipide treatment of the human ocular surface: a case report.","volume":"9","author":"Kase","year":"2015","journal-title":"Exp Ther Med"},{"key":"R46-20260622","first-page":"406","article-title":"Treatment of dry eye after refractive surgery with rebamipide ophthalmic suspension: a comparative study.","volume":"11","author":"Takahashi","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"R47-20260622","doi-asserted-by":"crossref","first-page":"15210","DOI":"10.1038\/s41598-017-13121-9","article-title":"A prospective, randomized trial of two mucin secretogogues for the treatment of dry eye syndrome in office workers.","volume":"7","author":"Shimazaki","year":"2017","journal-title":"Sci Rep"},{"key":"R48-20260622","doi-asserted-by":"crossref","first-page":"89","DOI":"10.18231\/j.ijceo.2024.015","article-title":"Comparative efficacy of cyclosporine 0.1%, rebamipide 2%, and carboxymethylcellulose-cyclosporine 0.05% eye drops in the management of dry eye disease among the Indian population.","volume":"10","author":"Bansal","year":"2024","journal-title":"Indian J Clin Exp Ophthalmol"},{"issue":"Suppl 1","key":"R49-20260622","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/ICL.0000000000000643","article-title":"A new perspective on dry eye classification: proposal by the Asia Dry Eye Society.","volume":"46","author":"Tsubota","year":"2020","journal-title":"Eye Contact Lens"},{"key":"R50-20260622","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ajhg.2024.06.007","article-title":"Structural and genetic diversity in the secreted mucins MUC5AC and MUC5B.","volume":"111","author":"Plender","year":"2024","journal-title":"Am J Hum Genet"},{"key":"R51-20260622","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2478\/bjmg-2013-0032","article-title":"Ethnic variation in interleukin-6 -174 (g\/c) polymorphism in the Malaysian population.","volume":"16","author":"Gan","year":"2013","journal-title":"Balkan J Med Genet"},{"key":"R52-20260622","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1038\/s41598-017-08534-5","article-title":"Sodium hyaluronate in the treatment of dry eye syndrome: a systematic review and meta-analysis.","volume":"7","author":"Ang","year":"2017","journal-title":"Sci Rep"},{"key":"R53-20260622","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/bjophthalmol-2012-302568","article-title":"Towards a dynamic customised therapy for ocular surface dysfunctions.","volume":"97","author":"Aragona","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R54-20260622","first-page":"CD009327","article-title":"Autologous serum eye drops for dry eye.","volume":"8","author":"Pan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R55-20260622","first-page":"425","article-title":"Efficacy of combination therapy of rebamipide and cyclosporine A in dry eye patients: a randomized clinical trial.","volume":"38","author":"Tsubota","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"R56-20260622","first-page":"231","article-title":"Long-term effects of rebamipide and diquafosol combination therapy in patients with refractory dry eye.","volume":"13","author":"Takamura","year":"2019","journal-title":"Clin Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:09:29Z","timestamp":1782119369000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":54,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048424","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"2025-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}